Abstract

Field of the Disclosure:

The present disclosure relates to acid addition salts of N-[5-[[4-[4-[(dimethylamino) methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl] acrylamide of formula-1 referred to as Lazertinib which is represented by the following structural formula.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS